Sign in
Taking people in South KoreaNo phase

Blood and Brain Imaging Study of Memory Disorders Such as Alzheimer Disease

Collects blood samples and brain scans from adults with memory problems and healthy controls.

Key facts

Who runs it
Yonsei University
Where
Seoul, South KoreaSee the site
Trial code
Registry title
Clinical Cohort of Memory Disorders
Status
Recruiting
People taking part
1,550 people, planned
Started
10 Sept 2020
Expected to end
9 Sept 2030
Type of study
Observational, 2 groups
Record updated
19 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 50 or older (memory disorder group) and healthy young adults aged 19-30 (comparison group). It collects blood samples and clinical and brain imaging data.

Age
Memory disorder group: 50 years or older. Healthy young adult group: 19-30 years.
Sex
Both sexes can join.

Main reasons for not taking part

  • Memory disorder group: uncontrolled acute or chronic infection, or another life-threatening illness of the body
  • Young adult group: any current medical, surgical, nerve or mental health condition (self-reported)
  • Young adult group: history of liver, kidney or heart disease (self-reported)
  • Young adult group: taking medication every day
  • Young adult group: severe head impact or loss of consciousness within the past year

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Healthy young adult controls: Adults of either sex aged 19-30 years. Participants must consent to participation. For patients with limited consent capacity and MMSE <15, additional consent from a family representative is obtained
  • Exclusuion Criteria Memory disorder cohort: Uncontrolled acute or chronic infection, or another life-threatening systemic illness
  • Healthy young adult controls:
  • Any current self-reported medical, surgical, neurological, or psychiatric condition
  • Self-reported history of liver, kidney, or heart disease
  • Daily medication use
  • Alcohol consumption on the day before blood collection
  • Severe impact to the head within the past year, including a motor vehicle accident or fall
  • Loss of consciousness for any reason within the past year

Where in South Korea

  • Yonsei University College of MedicineSeoul, South KoreaContact: Eosu Kim, ProfessorTaking people

About the trial

What the trial wants to find out

This observational study is designed as a multicenter clinical cohort to collect and bank blood specimens linked to clinical and brain imaging data for biomarker discovery and validation in memory disorders. The protocol lists Severance Hospital, Gangnam Severance Hospital, and Yongin Severance Hospital as study sites. Planned enrollment is 1,550 participants: 1,500 adults aged 50 years or older and 50 healthy young adult controls aged 19-30 years.

Read full original descriptionShow less

Participants are enrolled according to eligibility criteria and consent, irrespective of the specific medication received. Clinical information, cognitive assessments, and available brain magnetic resonance imaging (MRI) and positron emission tomography (PET) data will be collected to investigate diagnosis, disease severity, and clinical course. A total of 6 mL of research blood will be collected for banking, separated into plasma and buffy coat, and stored at -70°C. Young adult controls will provide a comparison for age-related and disease-related biomarker differences. The target follow-up duration for the memory disorder cohort is 5 years; young adult controls attend a single study visit. The overall study period is 120 months from IRB approval.

The 2 groups in the trial

  • Memory disorder cohort

    dults aged 50 years or older recruited at the three participating hospitals. The study focuses on the spectrum of memory disorders, including subjective memory impairment, mild cognitive impairment, and dementia. Blood specimens are linked to clinical data and available cognitive and neuroimaging assessments. Participants receiving anti-amyloid antibody treatment form a subgroup with repeated blood sampling before treatment, before the 5th, 7th, 14th, and 26th administrations, at week 72 or treatment termination, and when amyloid-related imaging abnormalities are suspected. Target enrollment: 1,500.

  • Healthy young adult controls

    Healthy adults aged 19-30 years recruited through university notice boards and online advertisements. Participants attend one visit for memory screening and blood collection, including hematology, clinical chemistry, and APOE genotyping. Demographic information, height, weight, Mini-Mental State Examination, Clinical Dementia Rating, and Global Deterioration Scale are collected. Target enrollment: 50 (25 men and 25 women) at Severance Hospital.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Clinical Cohort of Memory Disorders
Plain-language title
Blood and Brain Imaging Study of Memory Disorders Such as Alzheimer DiseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
19 October 2026